JP2021527126A5 - - Google Patents

Info

Publication number
JP2021527126A5
JP2021527126A5 JP2021518047A JP2021518047A JP2021527126A5 JP 2021527126 A5 JP2021527126 A5 JP 2021527126A5 JP 2021518047 A JP2021518047 A JP 2021518047A JP 2021518047 A JP2021518047 A JP 2021518047A JP 2021527126 A5 JP2021527126 A5 JP 2021527126A5
Authority
JP
Japan
Prior art keywords
nitrogen
pharmaceutical composition
partially unsaturated
independently selected
membered
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2021518047A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021527126A (ja
JP7481329B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2019/035846 external-priority patent/WO2019236890A1/en
Publication of JP2021527126A publication Critical patent/JP2021527126A/ja
Publication of JP2021527126A5 publication Critical patent/JP2021527126A5/ja
Application granted granted Critical
Publication of JP7481329B2 publication Critical patent/JP7481329B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2021518047A 2018-06-07 2019-06-06 Sarm1阻害剤 Active JP7481329B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862682054P 2018-06-07 2018-06-07
US62/682,054 2018-06-07
PCT/US2019/035846 WO2019236890A1 (en) 2018-06-07 2019-06-06 Inhibitors of sarm1

Publications (3)

Publication Number Publication Date
JP2021527126A JP2021527126A (ja) 2021-10-11
JP2021527126A5 true JP2021527126A5 (cg-RX-API-DMAC7.html) 2023-02-10
JP7481329B2 JP7481329B2 (ja) 2024-05-10

Family

ID=68770700

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021518047A Active JP7481329B2 (ja) 2018-06-07 2019-06-06 Sarm1阻害剤

Country Status (6)

Country Link
US (1) US12624026B2 (cg-RX-API-DMAC7.html)
EP (1) EP3801503A4 (cg-RX-API-DMAC7.html)
JP (1) JP7481329B2 (cg-RX-API-DMAC7.html)
CN (2) CN112867489A (cg-RX-API-DMAC7.html)
MA (1) MA52812A (cg-RX-API-DMAC7.html)
WO (1) WO2019236890A1 (cg-RX-API-DMAC7.html)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7478142B2 (ja) 2018-06-07 2024-05-02 ディスアーム セラピューティクス, インコーポレイテッド Sarm1阻害剤
CA3102645A1 (en) 2018-06-07 2019-12-12 Disarm Therapeutics, Inc. Inhibitors of sarm1
CN112955150A (zh) * 2018-10-19 2021-06-11 达萨玛治疗公司 与nad+或nad+前体组合的sarm1抑制剂
CA3123215C (en) 2018-12-19 2024-04-02 Disarm Therapeutics, Inc. Inhibitors of sarm1 in combination with neuroprotective agents
US12624025B2 (en) * 2019-06-06 2026-05-12 Disarm Therapeutics, Inc. Inhibitors of SARM1
JP7319395B2 (ja) 2019-06-14 2023-08-01 ディスアーム セラピューティクス, インコーポレイテッド Sarm1の阻害剤
WO2021050913A1 (en) 2019-09-12 2021-03-18 Disarm Therapeutics, Inc. Inhibitors of sarm1
WO2021108602A1 (en) * 2019-11-26 2021-06-03 Disarm Therapeutics, Inc. Methods and compositions for neuroprotection
EP4083037A4 (en) * 2019-12-26 2024-01-24 Yonsei University, University-Industry Foundation(UIF). Pyrrolidine derivative, and pharmaceutical composition for preventing or treating beta-amyloid or tau protein-associated diseases containing same
AU2021206651B2 (en) * 2020-01-07 2024-02-22 Disarm Therapeutics, Inc. Inhibitors of SARM1
CA3174321A1 (en) 2020-04-09 2021-10-14 Disarm Therapeutics, Inc. Indazole derivatives as inhibitors of sarm1
WO2021207308A1 (en) 2020-04-09 2021-10-14 Disarm Therapeutics, Inc. Condensed pyrazole derivatives as inhibitors of sarm1
EP4192828A1 (en) 2020-08-04 2023-06-14 Nura Bio, Inc. Substituted pyridine derivatives as sarm1 inhibitors
TW202334117A (zh) 2020-08-24 2023-09-01 美商達薩瑪治療公司 Sarm1之抑制劑
WO2022060812A1 (en) * 2020-09-16 2022-03-24 Nura Bio, Inc. Substituted pyridine derivatives as sarm1 inhibitors
CN117797146A (zh) * 2020-11-12 2024-04-02 科辉智药生物科技(无锡)有限公司 Sarm1酶活性抑制剂及其在神经退行性疾病中的应用
CA3200439A1 (en) * 2020-12-08 2022-06-16 Disarm Therapeutics, Inc. Benzopyrazole inhibitors of sarm1
KR20240041987A (ko) 2021-07-28 2024-04-01 누라 바이오, 인크. Sarm1 억제제로서 치환된 피리딘 유도체
WO2023193809A1 (zh) * 2022-04-08 2023-10-12 深圳众格生物科技有限公司 Sarm1抑制剂化合物、包含其的药物组合物及其制备方法和用途

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA847926B (en) 1983-10-17 1986-05-28 Lilly Co Eli 3-bicyclicpyridinium-methyl cephalosporins
EP0187456A1 (en) 1984-11-29 1986-07-16 Ici Pharma Cephalosporin derivatives
UA60365C2 (uk) 1998-06-04 2003-10-15 Пфайзер Продактс Інк. Похідні ізотіазолу, спосіб їх одержання, фармацевтична композиція та спосіб лікування гіперпроліферативного захворювання у ссавця
CA2443918C (en) 2001-04-11 2012-06-05 Senju Pharmaceutical Co., Ltd. Visual function disorder improving agents containing rho kinase inhibitors
US6989451B2 (en) * 2002-06-04 2006-01-24 Valeant Research & Development Heterocyclic compounds and uses thereof
US6727241B2 (en) * 2002-06-12 2004-04-27 Chemocentryx Anti-inflammatory compositions and methods of use
JP2006516603A (ja) 2003-01-27 2006-07-06 ファイザー・プロダクツ・インク イソチアゾール誘導体
WO2005082001A2 (en) 2004-02-20 2005-09-09 The Scripps Research Institute Advanced isothiazole based protein kinase inhibitors
US7429667B2 (en) 2005-01-20 2008-09-30 Ardea Biosciences, Inc. Phenylamino isothiazole carboxamidines as MEK inhibitors
US20060217390A1 (en) * 2005-02-24 2006-09-28 Esmir Gunic Cycloalkl, aryl and heteroaryl amino isothiazoles for the treatment of Hepatitis C virus
US7557103B2 (en) 2005-04-05 2009-07-07 Eli Lilly And Company Imidazopyridazine compounds
WO2006133417A1 (en) * 2005-06-07 2006-12-14 Valeant Pharmaceuticals International Phenylamino isothiazole carboxamidines as mek inhibitors
WO2008118626A2 (en) 2007-03-08 2008-10-02 Burnham Institute For Medical Research Inhibitors of jnk and methods for identifying inhibitors of jnk
US8242271B2 (en) 2007-06-04 2012-08-14 Avila Therapeutics, Inc. Heterocyclic compounds and uses thereof
US8067452B2 (en) 2007-06-21 2011-11-29 Valeant Pharmaceuticals International 3-hydroxyisothiazole-4-carboxamidine derivatives as CHK2 inhibitors
US20100324049A1 (en) 2007-09-27 2010-12-23 Makoto Ando Diaryl ketimine derivative having antagonism against melanin-concentrating hormone receptor
JP5576370B2 (ja) 2008-08-06 2014-08-20 ファイザー・インク Chk−1阻害剤としての6置換2−ヘテロシクリルアミノピラジン化合物
WO2011019678A1 (en) 2009-08-11 2011-02-17 Allergan, Inc. Isothiozoles for treating conditions of the eye
CA2780922A1 (en) 2010-02-11 2011-08-18 OSI Pharmaceuticals, LLC 7-aminofuropyridine derivatives
USRE47009E1 (en) 2011-02-01 2018-08-28 The Children's Hospital Of Philadelphia HDAC inhibitors and therapeutic methods using the same
DE102011009961A1 (de) 2011-02-01 2012-08-02 Merck Patent Gmbh 7-Azaindolderivate
WO2012178022A2 (en) 2011-06-24 2012-12-27 University Of Massachusetts Therapeutic applications targeting sarm1
GB201310460D0 (en) 2013-06-12 2013-07-24 Lytix Biopharma As Compounds
WO2018011628A1 (en) 2016-07-11 2018-01-18 Lifesci Pharmaceuticals, Inc. Therapeutic inhibitory compounds
EP4091622A1 (en) 2016-08-16 2022-11-23 Henry Ford Health System Compositions for the treatment of chemotherapy-induced neuropathic pain
EP3515426A1 (en) 2016-09-24 2019-07-31 Washington University INHIBITORS OF SARM1 NADase ACTIVITY AND USES THEREOF
TWI763722B (zh) 2016-10-14 2022-05-11 美商林伯士拉克許米公司 Tyk2抑制劑及其用途
IL251949A0 (en) * 2017-04-26 2017-07-31 Medical Res Infrastructure & Health Services Fund Tel Aviv Medical Ct Small organic molecules for use in the treatment of neuro-inflammatory diseases
CA3102645A1 (en) 2018-06-07 2019-12-12 Disarm Therapeutics, Inc. Inhibitors of sarm1
JP7478142B2 (ja) 2018-06-07 2024-05-02 ディスアーム セラピューティクス, インコーポレイテッド Sarm1阻害剤
CA3123215C (en) * 2018-12-19 2024-04-02 Disarm Therapeutics, Inc. Inhibitors of sarm1 in combination with neuroprotective agents
US12624025B2 (en) 2019-06-06 2026-05-12 Disarm Therapeutics, Inc. Inhibitors of SARM1

Similar Documents

Publication Publication Date Title
JP2017537940A5 (cg-RX-API-DMAC7.html)
RU2017101829A (ru) Пиразоловые соединения в качестве модуляторов fshr и пути их применения
JP2018538248A5 (cg-RX-API-DMAC7.html)
RU2007101653A (ru) Производные 1-азабицикло[3.3.1]нонанов
RU2019131017A (ru) Соединения гетероарила в качестве ингибиторов btk и их применение
RU2020123151A (ru) Антагонисты tlr7/8 и их применение
JP2022514385A5 (cg-RX-API-DMAC7.html)
JP2018511647A5 (cg-RX-API-DMAC7.html)
JP2024528986A5 (cg-RX-API-DMAC7.html)
JP2019514884A5 (cg-RX-API-DMAC7.html)
JP2010523522A5 (cg-RX-API-DMAC7.html)
JP2018522866A5 (cg-RX-API-DMAC7.html)
JP2016518437A5 (cg-RX-API-DMAC7.html)
JP2021523200A5 (cg-RX-API-DMAC7.html)
RU2013108348A (ru) Конденсированные гетероарилы и их применение
JP2013518050A5 (cg-RX-API-DMAC7.html)
JP2013010792A5 (cg-RX-API-DMAC7.html)
JP2011529918A5 (cg-RX-API-DMAC7.html)
JP2021504314A5 (cg-RX-API-DMAC7.html)
RU2008107733A (ru) Ингибиторы gsk-3
JP2019516739A5 (cg-RX-API-DMAC7.html)
JP2019520344A5 (cg-RX-API-DMAC7.html)
RU2016101958A (ru) Пиразольные соединения в качестве модуляторов fshr и их применение
JP2017525699A5 (cg-RX-API-DMAC7.html)
RU2018132559A (ru) Связывающие молекулы для max в качестве модуляторов myc и их применения